SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (5384)9/22/1998 9:20:00 PM
From: scaram(o)uche   of 6136
 
Izzy:

The key selling points, if you want to call them that (Glaxo wants to!), are penetration of the blood brain barrier and a resistance profile that may differ from other PIs, dictated perhaps by changes at residue 50.

Glaxo appears to be targeting those that are afraid of lipodystrophy, but they don't have a leg to stand on other than fear, to my knowledge. Given the rash and what looks like equivalent efficacy at best, it's going to be a tough sell. Nelf is firmly entrenched as the PI of choice.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News